As part of the international evaluation program coordinated by ILSI/HESI, the potential of DNA repair deficient Xpa −/− mice and the double knockout Xpa −/− .p53 +/− mice for short term carcinogenicity assays was evaluated. For comparison also wild-type C57BL/6 mice (WT) were included in these studies. Four test compounds were administered to groups of 15 male and 15 female Xpa −/− mice, Xpa −/− .p53 +/− mice and WT mice for 39 weeks. The model compounds investigated were haloperidol, reserpine (nongenotoxic rodent carcinogens, putative human noncarcinogens), phenacetin (genotoxic rodent carcinogen, suspected human carcinogen), and D-mannitol (noncarcinogen in rodents and humans). The test compounds were administered as admixture to rodent diet at levels up to 25 mg/kg diet for haloperidol, 7.5 mg/kg diet for reserpine, 0.75% for phenacetin, and 10% for D-mannitol. These levels included the maximum tolerable dose (MTD). Survival was not affected with any of the test compounds. Haloperidol, reserpine and D-mannitol were negative in the carcinogenicity assay with Xpa −/− and Xpa −/− .p53 +/− mice, showing low and comparable tumor incidences in controls and high-dose animals. The results obtained with phenacetin may be designated equivocal in Xpa −/− .p53 +/− mice, based on the occurrence of a single rare tumor in the target organ (kidney) accompanied by a low incidence of hyperplastic renal lesions and a high incidence of karyomegaly. These results are in agreement with the currently known carcinogenic potential of the 4 test compounds in humans.
INTRODUCTION
Cancer is a worldwide public health concern. Exposure to natural and synthetic chemicals is known to be a major determinant of cancer in humans. Reduction of cancer risk by the identification of human carcinogens and limiting human exposure is therefore important. At present (putative) human carcinogens are identified by testing of compounds in 2-year rat or 18-months mouse bioassays and occasionally by epidemiological studies. These methods have severe limitations in that they are slow, expensive, relatively insensitive, and hampered by many uncertainties.
Since cancer is a multistage process it is expected that transgenic animals, which have already undergone one step in the cancer process may present a sensitive alternative for the 2-year rodent bioassay. Several transgenic mouse models harboring either an activated oncogene or an inactivated tumor suppressor gene have already been investigated for this purpose (Tennant et al., 1995; Yamamoto, 1996) . The sensitivity of such models may depend however on the expression pattern of the transgene in different tissues and/or its involvement in the specific tumor process. Transgenic DNA repair-deficient Xpa −/− mice, generated at the National Institute of Public Health and the Environment in the Netherlands (de Vries et al., 1995) , have been postulated as a suitable third type of candidate mouse model. These mice are impaired in a relevant step of the multistage cancer process (accumulation of genetic damage) and should not display specific tissue restrictions . Xpa −/− mice were shown to have an increased susceptibility to skin tumor development when treated with genotoxic stimuli like UV-B radiation or dimethyl-benz[a]antracene (de Vries et al., 1995; Berg et al., 1997) . In addition, oral administration of genotoxic carcinogens such as benzo[a]pyrene (B[a]P) resulted in a more rapid and increased tumor incidence (lymphomas) in Xpa −/− mice when compared with treated wild-type (C57BL/6) mice. Also a very low spontaneous tumor incidence was observed in untreated Xpa −/− mice not only before but also after 12 months of age . Finally, the Xpa −/− mice have also been crossed with p53 +/− mice to generate the double knockout mice Xpa −/− .p53, +/− which are expected to have a further enhanced sensitivity towards genotoxic carcinogens due to the diminished cell cycle arrest and/or reduced apoptotic response (Van Oostrum et al., 1999) . Both the Xpa −/− and the Xpa −/− p53 +/− model have become part of an international initiative on the evaluation of alternative short-term carcinogenicity assays, which includes 3 other transgenic mouse models (p53 +/− , TG.AC, and rasH2), coordinated by ILSI/HESI, Washington, USA (Robinson 1998; Robinson and McDonald, 2001) .
Within the ILSI/HESI program several classes of carcinogens were tested in the various alternative models. Within this framework the purpose of the present studies was to evaluate the carcinogenic potential of haloperidol and reserpine (both nongenotoxic rodent carcinogens, putative human noncarcinogens), phenacetin (genotoxic rodent carcinogen and suspected human carcinogen) and D-mannitol (nonrodent, nonhuman carcinogen) .
Haloperidol, a dopamine receptor antagonist, is used as antipsychotic agent. The drug produces an increase in serum prolactin. In an 18-month carcinogenicity study in albino Swiss CD1 mice, performed by Janssen Pharmaceutica (Experiment no. 1082 (Experiment no. , completed 1984 , haloperidol induced pituitary gland hyperplasia and adenomas as well as mammary gland hyperplasia and adenocarcinomas at dietary levels of 6.3 and 25 ppm (mg/kg feed) but not at 1.6 ppm.
Reserpine is a naturally occurring alkaloid that inhibits vascular uptake of catecholamines and serotonin. It is primarily used as a peripheral antihypertensive and as a central depressant and sedative. In B6C3F 1 mice chronic administration of reserpine (at levels of 5 or 10 ppm) induced mammary adenocarcinomas and undifferentiated carcinomas of the seminal vesicles (NTP, 1980; IARC Monographs, 1980) . Reserpine was found earlier not to be carcinogenic for p53 +/− mice after 6 months oral exposure (Tennant et al., 1995) .
Phenacetin is a drug with analgesic and anti-pyretic properties. It is known to induce methemoglobinaemia and hemolytic anemia. In a classical carcinogenicity study in mice, tumors of the kidney and urinary bladder were induced at a dietary concentration of 1.25% phenacetin (IARC Monographs, 1980) . However, the mechanism behind its carcinogenic potential is not well defined. In humans, a positive association between the use of phenacetin-containing analgesics and cancer of the renal pelvis and urinary bladder has been established (IARC Monographs, 1987). D-mannitol, a noncarcinogen in rodents (NTP, 1982; Lina et al., 1996) , is used in a wide variety of food processing applications as a sweetener or as a flavor carrier/enhancer, and is used as an osmotic diuretic.
The carcinogenic response of these four model compounds was examined in the transgenic mouse Xpa −/− model and Xpa −/− .p53 +/− model, both in a C57BL/6 genetic background, and compared with the response of wild-type C57BL/6 mice (WT). The test compounds were mixed into the diet, and the study duration was nine months. Clinical observations, growth, food intake, organ weights, macroscopic examination at necropsy and microscopic examination of a large number of organs and tissues were used as criteria for disclosing possible compound-related effects.
MATERIALS AND METHODS

Animals and Maintenance
Xpa −/− knockout mice (C57BL/6 Xpa −/− ), double transgenic Xpa −/− .p53 +/− mice (C57BL/6 Xpa −/− .p53 +/− ) and wild-type mice (C57BL/6) were obtained from the National Institute of Public Health and the Environment, Bilthoven, The Netherlands. At the start of studies the mice were 9-13 weeks old.
The welfare of the animals was maintained in accordance with the general principles of the European Communities (Directive 86/609/EEC) and the Netherlands legislation (the Experiments on Animals Act 1997), governing the use of animals in toxicity experiments. The mice were kept under conventional conditions in macrolon cages with sterilized dust-free wood savings as bedding material, 5 per cage. The phenacetin and reserpine-treated mice were kept in an isolator. The isolator and the animal rooms were ventilated with about 10 air changes per hour, maintained at a temperature of 22 • ± 3 • C and a relative humidity of at least 40%. Lighting was artificial with a sequence of 12 hours light and 12 hours dark. Feed and drinking water were provided ad libitum. Tap water for human consumption was given in polypropylene bottles, which were cleaned weekly and filled up when necessary. The feed was provided as pellets, in feed hoppers and was changed at least once per week. Reserpine and phenacetin were mixed through a commercial SRM-A like rodent diet, obtained from Altromin, Lage, Germany. Haloperidol and D-mannitol were mixed through a commercial rodent diet (Rat & Mouse No. 3 Breeding Diet) obtained from SDS, Special Diets Services, Witham, England. All test diets were stored in a freezer until use.
Test Compounds and Dose-Levels
Haloperidol was obtained from Janssen Pharmaceutica N.V., Beerse, Belgium. Reserpine and Phenacetin were obtained from Sigma-Aldrich B.V. and D-mannitol was a gift from Cerestar Int., Brussels, Belgium.
The dose levels of haloperidol (0, 1.6, 6.3, and 25 mg/kg body weight/day) were selected on the basis of growth retardation and increased development of the mammary glands observed at dietary levels of 25 and 50 ppm in a 4-wk rangefinding study with Xpa −/− transgenic mice (Lina, 2001; TNO report V 98.335 ) and comparison with an 18-month study with CD1 Swiss mice (Janssen Pharmaceutica 1984; Experiment no. 1082).
A dose-range finding study was not performed with reserpine. The dose selection for this compound was based on a previous study in which exposure to 10 ppm reserpine in the feed caused excessive weight loss and mortality in p53 +/− mice (Tennant et al., 1995) . In the present study dose levels of 0 (controls), 1.0, 2.5, and 5.0 ppm (mg/kg diet) reserpine were chosen. For Xpa −/− mice, an additional top-dose (7.5 ppm) group was added in order to study the effect of severe toxicity on the carcinogenic potential of this compound.
The dose selection of phenacetin was based on data from a 4-week dose-range finding study. For toxicological evaluation, 5 male and 5 female Xpa −/− mice were exposed to 0, 0.1, 0.25, 0.5, or 0.75% phenacetin in the feed. Body weight gain of male mice treated with 0.75% phenacetin was markedly decreased. Also a tendency towards anemia and a dose-dependent increase in splenic weight were observed. On the basis of these observations, levels of 0 (controls), 0.25, 0.5, and 0.75% phenacetin were selected for the 9-month carcinogenicity study in transgenic Xpa −/− mice. D-mannitol was incorporated in the diet at levels of 0 (controls), 2, 5, and 10%. The dose selection for D-mannitol was based on NTP carcinogenicity studies in B6C3F1 mice and F344 rats (NTP, 1982) with dietary level up to 5%, and a carcinogenicity study in Wistar rats in which D-mannitol was used as reference substance at a dietary level of 10% (Lina et al., 1996) . TOXICOLOGIC PATHOLOGY
Experimental Design
The previously stated levels of the 4 test compounds were administered to groups of 15 male and 15 female transgenic Xpa −/− mice. In addition, the control and the top-dose diet of each of these test compounds was administered to groups of 15 male and 15 female double transgenic Xpa −/− p53 +/− mice and to groups of 15 male and 15 female wild-type (WT) mice. Exposure was 39 weeks for all groups. A positive control group was not included in the present studies, since 2 positive control compounds (2-AAF, p-cresidine) were examined in a concurrent study at RIVM, the results of which have been published previously .
Clinical signs and survival were checked daily. From three months after the start of the study, grossly visible or palpable masses were recorded weekly. Body weights of the individual mice were determined weekly or (from 2 months) once every 2 weeks. The quantity of feed consumed by the animals in each cage was measured over 1-week periods and the intake of test compound per kg body weight was calculated. All mice that died, became moribund, or showed marked disturbed general condition during the study were sacrificed and necropsied. At termination, all the remaining mice were sacrificed by exsanguination under ether anesthesia and necropsied. The liver, kidneys, spleen, testes, heart, thymus, and brain were weighed. Tissue specimens were collected from adrenal glands, aorta, bone marrow (femur and sternum), brain, caecum, cervical lymph nodes, coagulating glands, colon, epididymides, exorbital lachrymal glands, eyes, Harderian/lachrymal glands, heart, joint-knee (femur), kidneys, liver, lungs, mammary glands (females only), mesenteric lymph nodes, nerve-peripheral (sciatic), oesophagus, ovaries, pancreas, parathyroids, parotid salivary glands, pituitary, prostate, rectum, seminal vesicles, skeletal muscle, skin, subcutis, small intestines (duodenum, ileum, jejunum), spinal cord, spleen, sternum with bone marrow, stomach (glandular and nonglandular), sublingual salivary glands, submaxillary salivary glands, testes, thymus, thyroid, trachea/bronchii, urinary bladder, uterus, vagina/ cervix, and also from all gross lesions.
The tissues required for microscopic examination were embedded in paraffin wax, sectioned at 5 µm and stained with hematoxylin and eosin according to the institute's routine procedures which closely resemble the RITA guidelines (Bahneman et al., 1995) . Microscopic examination included all tissues from the high-dose knockout mice (Xpa −/− and Xpa −/− .p53 +/− ), their respective controls, and the treated (high-dose) WT mice. In addition, the tissues of the decedents from all groups were examined. The study and all procedures were approved by the Animal Ethics Committee of the National Institute of Public Health and the Environment.
Statistics
Body weights and organ weights were evaluated by Analysis of variance (ANOVA) followed by Dunnett's multiple comparison tests. Bartlett's test for homogeneity of variances preceded the above analyses. In case of inhomogeneity of variances, organ weights were evaluated by Kruskal-Wallis Anova followed by Mann-Whitney U -tests. Statistical analysis was conducted by comparing the test groups with their respective controls. The incidences of (pre)neoplastic histopathological changes were evaluated by Fisher's exact probability test (1-sided) included in the PLACES data acquisition software, by comparing the high-dose groups with their respective control groups. A p value of less than 0.05 was considered to indicate statistical significance.
RESULTS
Haloperidol
In males, mean body weights were decreased in the highdose groups of all 3 genotypes as compared to their respective controls. Although these changes were generally statistically significant throughout the study, the differences in terminal body weights did not reach the level of statistical significance in the Xpa −/− p53 +/− and wild-type groups (Table 1 ; only terminal body weights are shown). In females, mean body weights were higher in all high-dose groups as compared to their respective controls throughout the study (generally statistically significant in the Xpa −/− p53 +/− and wild-type high-dose groups only). This is a well-known phenomenon following administration of neuroleptics to female animals. For all 3 genotypes the mean food intake was generally lower in the treatment groups than in their respective controls. These effects were most pronounced in males of all high-dose groups and in males of the Xpa −/− mid dose groups (data not shown). Mortality was low; a total number of 11 mice randomly distributed over the various groups died intercurrently. The incidence of visible or palpable masses was low, as was the overall mortality rate (<4%). The overall intake of haloperidol in the Xpa −/− low-and mid dose group was 0.3 and 1.1 mg/kg bw/day, respectively. The intake in the high-dose groups was between 4.0-4.3 mg/kg bw/day for all genotypes.
Relative weights of the kidneys were increased in males of the Xpa −/− and the Xpa −/− p53 +/− high-dose groups ( Table 1 ). The relative weight of the thymus was increased in males of the Xpa −/− high-dose group and decreased in females of the Xpa −/− p53 +/− high-dose group (Table 1) . The relative weight of the spleen and the heart were decreased in females of the Xpa −/− p53 +/− and wild-type high-dose groups. Relative weight of the heart was increased in males of the Xpa −/− mid-and high-dose group, and in males of the WT high-dose group (Table 1) .
Macroscopic examination at autopsy did not show treatment-related changes. Microscopic examination did not reveal any treatment-related tumors. The treatment with haloperidol was, however, associated with hyperplasia of the mammary glands. This proliferative change was observed in 5/13 females of the Xpa −/− p53 +/− high-dose group, 7/15 females of the WT high-dose group and in one female of the Xpa −/− high-dose group (Table 5 ; data obtained in WT mice not shown).
In addition, some nonneoplastic lesions were ascribed to treatment (data not shown). In the pituitary, pars intermedia hypertrophy occurred in most male and female transgenic and WT mice of the high-dose groups and in 2 out of 14 females of the mid dose Xpa −/− group. In the mammary glands, ductal dilatation was seen in 2/15; 9/13 and 11/15 female highdose animals of the Xpa −/− , the Xpa −/− p53 +/− and the WT group, respectively. In the Xpa −/− high-dose group increases in the incidences of seminiferous tubular atrophy in the testes Vol. 32, No. 2, 2004 CARCINOGENICITY TESTING IN Xpa AND Xpa/ p53 KNOCKOUT MICE 195 (8/14 vs 2/15 in controls) and in epithelial mucification of the vagina (6/15 vs 0/15 in controls) were found.
Reserpine
In Xpa −/− mice of both sexes, exposure to 5.0 and 7.5 ppm reserpine induced a decrease in body weight that often reached the level of statistical significance throughout the study (only terminal body weights are shown in Table 2 ). In female, but not in male, Xpa −/− p53 +/− mice, body weights were significantly decreased at 5.0 ppm reserpine through- out the study. Feed intake was generally lower in all groups fed reserpine than in their respective controls. In female Xpa −/− mice this decrease was dose-related. Visible or palpable masses were not found. Mortality was low; a total number of 13 mice randomly distributed over the various groups died intercurrently. The overall intake of reserpine was approx. 0.1, 0.3, 0.6, and 0.9 mg/kg bw/day in the groups fed 1, 2.5, 5, and 7.5 ppm reserpine, respectively. Relative weight of the kidneys was increased at the higher dose levels of reserpine in Xpa −/− males (5.0 and 7.5 ppm), 196 LINA ET AL. TOXICOLOGIC PATHOLOGY Xpa −/− females (7.5 ppm) and in Xpa −/− p53 +/− males at 5.0 ppm. In WT females exposed to 5.0 ppm reserpine relative kidney weight was, however, decreased (Table 3) . Relative weight of the spleen was increased in Xpa −/− males at 5.0 and 7.5 ppm and in Xpa −/− p53 +/− females at 5.0 ppm. Relative weight of the thymus was increased in Xpa −/− p53 +/− and WT females at 5.0 ppm and relative heart weight was increased in female Xpa −/− mice at 7.5 ppm (Table 3) . Gross examination at autopsy showed discoloration of the seminal vesicles in all three genotypes treated with 5.0 or 7.5 ppm reserpine. At these dose levels, altered luminal content and focal fibrosis of the seminal vesicles were observed in a few animals (1-4) of these groups. Moreover, a statistically significant increase in the incidence of Xpa −/− p53 +/− females with lactating mammary glands (6/15 in the 5 ppm group vs 0/13 in controls) was observed. These observations are considered toxicologically relevant because they did not occur in controls and, moreover, seminal vesicles and mammary glands were the target organs in a previous NTP study (NTP, 1980) . A number of tumors was observed exclusively in Xpa −/− p53 +/− mice. In a treated male a hemangioma was observed in the spleen. In Xpa −/− p53 +/− females, a localized lymphoma, an adenoma in the Harderian gland, an osteofibroma in the knee, an ependymoma in the brain, a hemangioma in the liver and an adenocarcinoma in the mammary gland were observed. The occurrence of these various single tumors of different origin and arising in different tissues resulted in a relatively high total tumor incidence (47%) in females of this group.
Phenacetin
The feeding of phenacetin resulted in dose-related decreases in body weight in Xpa −/− and Xpa −/− p53 +/− mice of both sexes (only terminal body weights are shown in Table 3 ). The differences with the controls were statistically significant throughout the study at all dose levels in males and at 0.5% and 0.75% in females. In WT mice, feeding of 0.75% phenacetin did not significantly affect body weight. Food intake was decreased in all groups fed phenacetin as compared to their respective controls. Visible or palpable masses were not found. Mortality rate was very low. In total six males randomly distributed over the various groups died intercurrently. The overall intake of phenacetin (males and females combined) was approx. 300 and 600 mg/kg bw/day in the Xpa −/− low-and mid dose group. The intake in the high-dose groups was approx. 900 mg/kg bw/day for males and approx. 1,000 mg/kg bw/day for females.
Relative weight of the spleen was increased in Xpa −/− , Xpa −/− p53 +/− and WT mice of both sexes at 0.5% and/or 0.75% phenacetin. Increases in relative weight of the heart were found in Xpa −/− males at 0.75%, in Xpa −/− females at 0.5 and 0.75% and in Xpa −/− p53 +/− females at 0.75% phenacetin. Increases in relative liver weight occurred in WT males at 0.75% phenacetin and in Xpa −/− females at 0.5 and 0.75% phenacetin (Table 2) .
Macroscopic examination at autopsy did not reveal treatment-related changes. Renal proximal tubular hyperplasia was observed in 2 high-dose Xpa −/− males and in one high-dose Xpa −/− p53 +/− male, and one tubular adenoma was found in the kidney of a Xpa /− p53 +/− female mouse (Table 5 ). In addition, multifocal karyomegaly was observed in the proximal renal tubules of all male and female knockout mice, but not in WT animals (data obtained in WT mice are not shown in Table 5 ). This observation is notable, especially in relation to the hyperplasia and the adenoma observed in the knockout mice. In addition, olfactory epithelial degeneration was observed in the nose of most male and female transgenic and WT mice of the high-dose groups (nonneoplastic lesion; not shown in Table 5 ). Vol. 32, No. 2, 2004 CARCINOGENICITY TESTING IN Xpa AND Xpa/ p53 KNOCKOUT MICE 197 
D-Mannitol
Except for Xpa −/− p53 +/− (both sexes) and WT females, the feeding of 10% D-mannitol resulted in lower body weights as compared to their respective controls during the study (data not shown; only terminal body weights are given in Table 4 ). Mean feed intake was generally lower in all groups fed 10% D-mannitol. The effects were most marked in all high-dose males and in Xpa −/− p53 +/− females. Visible or palpable masses were not found. Mortality rate was very low. In total 7 mice randomly distributed over the various groups died intercurrently. The overall intake of D-mannitol was approx. 3.5 and 9 g/kg bw/day day in the Xpa −/− low-and middose group. The intake in the high-dose groups was approx. 16 g/kg bw/day for males and approx. 20 g/kg bw/day for females. Relative weight of the liver was increased in high-dose Xpa −/− p53 +/− males and in high-dose WT females, whereas relative liver weights were decreased in Xpa −/− males of all groups without a dose-response relationship (Table 4 ).
Relative thymus weight was decreased in high-dose Xpa −/− and high-dose WT males. Relative kidney weight was increased in female Xpa −/− mice of the mid-and highdose groups. Relative weight of the heart was increased in males of the high-dose Xpa −/− p53 +/− groups and in males of the high-dose WT group (Table 4) .
Macroscopic examination at autopsy did not show treatment-related changes. All nonneoplastic, hyperplastic and (pre)neoplastic lesions observed (including one sarcoma in the prostate and one astrocytoma, each in a male of the Xpa −/− p53 +/− high-dose group) are considered normal background pathology in mice of these stains and are not attributed to the administration of D-mannitol.
DISCUSSION AND CONCLUSIONS
The aim of the studies summarized in the present paper was to evaluate the suitability of DNA repair deficient Xpa transgenic mice for short term carcinogenicity testing. In the framework of an international program coordinated by ILSI/HESI this was done by investigating the carcinogenic potential of 4 different compounds in both the Xpa −/− and the double knockout Xpa −/− p53 +/− models. The test compounds used were haloperidol (a nongenotoxic, rodent carcinogen), reserpine (a rodent carcinogen, but putative human noncarcinogen), phenacetin (a rodent and human genotoxic carcinogen) and D-mannitol (a noncarcinogen in rodents and human).
Although occasionally some background tumors were found, exposure to haloperidol, reserpine, phenacetin, or Dmannitol, did not induce any specific tumors nor affected the incidence of preneoplastic lesions, in the WT, Xpa −/− , or in the Xpa −/− p53 +/− mice. The absence of carcinogenic potential of these compounds was not due to insufficient exposure. The growth reduction at the higher dose levels, although partly explained by reduced feed intake, demonstrated sufficient exposure. Moreover, the changes in the weight of various organs indicated that the MTD had been reached.
In a classical 18-months carcinogenicity assay in albino Swiss CD1 mice (Janssen Pharmaceutica; experiment no. 1082 , 1984 , haloperidol induced pituitary gland hyperplasia and adenomas as well as mammary gland hyperplasia and adenocarcinomas at dietary levels of 6.3 and 25 mg/kg feed. In the present study, haloperidol induced ductal dilatation and lobular hyperplasia of the mammary gland in highdose females of both transgenic genotypes and WT mice. Pars intermedia hypertrophy was observed in the pituitary of high-dose males and high-dose females of both transgenic genotypes and in the WT and in 2 Xpa −/− mid dose females. Surprisingly, the eosinophilic (prolactin-producing) cells in the pars distalis were not affected in any group. However, the present study with haloperidol in transgenic mice did not reveal any treatment-related tumors, despite the similarities in drug intake and nonneoplastic findings in both studies.
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Changes 0 ppm 25 ppm 0 ppm 25 ppm 0 ppm 7.5 ppm 0 ppm 5 ppm 0% 0.75% 0% 0.75% 0% 10% 0% 10% This negative tumor response shows that the Xpa −/− and Xpa −/− p53 +/− model is not overly sensitive for the nongenotoxic rodent carcinogen haloperidol. Apparently the study duration of 9 months was too short for this compound to show a positive tumor response in any of the 3 genotypes.
Adrenals
The relatively high total tumor incidence observed in reserpine-treated Xpa −/− p53 +/− female mice is remarkable, the more so as a number of these tumors are rather rare for mice of this age. However, according to the criteria defined by the ILSI pathology subcommittee (Popp, 2001) , the present results obtained with reserpine do not justify the conclusion that reserpine is carcinogenic in female Xpa −/− p53 +/− mice. Each of these rare tumors concerned single occurrences, and associated hyperplastic or preneoplastic lesions were absent. The carcinogenicity of reserpine in B6C3F 1 mice, as reported in a NTP study (NTP, 1980) in which chronic treatment resulted in mammary gland adenocarcinomas and undifferentiated carcinomas of the seminal vesicles, was not confirmed in the present study with Xpa transgenic mice. The present results are in agreement with those of Tennant et al. (1995) using p53 +/− mice, demonstratingthat 6 months oral treatment with identical dose levels of reserpine did not result in the development of treatment-related tumors.
In a classical carcinogenicity study with phenacetin in mice (Nakanishi et al., 1982) , tumors of the kidney and urinary bladder were induced at a dietary concentration of 1.25% phenacetin. In the present study with phenacetin, one Xpa −/− p53 +/− female mouse developed a renal tubular adenoma. Tubular adenomas are very rare in C57B1/6 mice at 9 months. Apart from this adenoma, a low incidence of proximal tubular hyperplasia, a putative pre neoplastic lesion, was observed in phenacetin-treated mice. In addition, multifocal karyomegaly was found in the kidneys of all high-dose male and female Xpa −/− -and Xpa /− p53 +/− mice. This change in the actual target tissue, which was not observed in WT mice, may indicate a response of these knockout mice to treatment with a genotoxic substance. Although karyomegaly as a putative preneoplastic change is still under debate, it may reflect a genotoxic insult, e.g., polyploidy. Recent mutation analysis of the kidneys of phenacetin-treated Xpa −/− LacZ mice (containing LacZ as reporter gene), supports this view (Luijten, personal communication). According to the criteria used in the ILSI project the phenacetin study was initially considered as negative, showing only a single tumor in the target organ. However, this single tumor is rare in Xpa −/− and C57Bl/6 mice, and was not only accompanied by a few hyperplastic changes, but also by extensive karyomegaly, which is now considered likely to reflect a genotoxic insult. Therefore, the conclusion might be justified that the carcinogenic potential of phenacetin should be considered as equivocal in the Xpa −/− p53 +/− model. This classification is not contradictory to the epidemiological observations and the results of previous long-term studies in mice, indicating that the carcinogenic potency of phenacetin appears to be rather low (weak genotoxic carcinogen).
In a concurrent control study, 2-AAF (300 mg/kg diet) used as positive control compound, clearly induced preneoplastic (proliferative) lesions in the liver (foci of cellular alteration and nodular hyperplasia) and urinary bladder (sim-ple hyperplasia and squamous metaplasia) of Xpa −/− and Xpa −/− p53 +/− mice, that were more pronounced than in treated WT mice . In addition, 2-AAF clearly induced liver tumors (hepatocellular adenoma and carcinoma ) and bladder tumors (transitional cell papilloma and carcinoma). These tumors were induced in Xpa −/− mice, with a particular robust response in the liver of females, and in Xpa −/− p53 +/− mice, showing a statistically significant response in the urinary bladder in both sexes. In treated WT male mice, 2 bladder tumors were observed. None of the untreated mice of any genotype showed liver or bladder tumors except for 1 liver adenoma in a WT male .
It can be concluded from the present results that haloperidol and reserpine, both nongenotoxic rodent carcinogens, and D-mannitol, a noncarcinogen in rodents and humans, are not carcinogenic in the Xpa knockout mouse model, whereas phenacetin, a rodent and human genotoxic carcinogen, gives results in the Xpa −/− p53 +/− mice that might be classified as equivocal. The rationale for the Xpa model is that it detects genotoxic carcinogens. The results of 3 of the 4 model compounds tested comply, whereas the fourth compound, phenacetin, does not contradict with this rationale. However, the overall results observed for both the Xpa −/− and Xpa −/− p53 +/− model within the ILSI/HESI program indicate that the specific sensitivity for genotoxic carcinogens is less absolute than originally expected . Positive tumor responses were obtained with some nongenotoxic human carcinogens like cyclosporin A and DES, and similar results were obtained for the p53 model as well (Storer et al., 2001) . Taking into account the data from all compounds tested so far with Xpa −/− and Xpa −/− p53 +/− mice, the specificity and sensitivity of in particular the Xpa −/− p53 +/− model is rather high and in line with that of other alternative models for carcinogenicity testing (Pritchard et al., 2003) .
The studies with Xpa −/− and Xpa −/− p53 +/− mice presently reported confirmed other findings. The original fear that these new models would be overly sensitive for chemicals did not prove correct. This is shown by the negative tumor response in 3 of the 4 nongenotoxic or noncarcinogenic compounds reported in the present paper, as well as in other negative studies like those reported for DEHP (Mortensen et al., 2002) or summarized elsewhere . The present findings with the Xpa −/− and Xpa −/− p53 +/− models are comparable with those from the classical 18-month bioassays. The studies also demonstrated that the spontaneous tumor incidence after 9 months is low: 5-7% in Xpa −/− and 9-13% in Xpa −/− p53 +/− mice (male-female).
Finally, the overall results of the ILSI/HESI programme , Pritchard et al., 2003 , indicate that the Xpa −/− and the Xpa −/− p53 +/− models are suitable models for short-term carcinogenicity testing. The carcinogen induced tumor spectrum is not different from WT mice but the number of tumors is greater and the latency time shorter . However, with a comparable specificity for tumor types induced, the Xpa −/− p53 +/− model gave in general a more robust response than the Xpa −/− model, which is most probably caused by the synergistic effect of both the DNA deficiency and the heterozygous p53 deficiency . Therefore, the use of Vol. 32, No. 2, 2004 CARCINOGENICITY TESTING IN Xpa AND Xpa/ p53 KNOCKOUT MICE 201 Xpa −/− p53 +/− mice in short-term carcinogenicity studies is preferred.
